{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.58","value":"11.33"},{"groupId":"OG001","spread":"2.08","value":"12.67"},{"groupId":"OG002","spread":"0","value":"12"},{"groupId":"OG003","spread":"0.78","value":"12.11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"9"}],"units":"Participants"}],"description":"Engraftment of Neutrophils: ANC recovery is defined as an absolute neutrophil count (ANC) of ≥ 0.5 x 109/L for three consecutive laboratory values obtained on different days. The day used as neutrophil engraftment is the date of the first of three laboratory values.\n\nGraft Failure: Graft failure includes failure to achieve neutrophil engraftment by day 22.","dispersionType":"Standard Deviation","groups":[{"description":"Carfilzomib 15 mg/m2 on days -2, -1, +5, and +6 IV over 10 minutes.\n\nCohort 1: Carfilzomib 15 mg/m2: Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 15 mg/m2 on day -2, -1, + 5 and +6","id":"OG000","title":"Cohort 1: Carfilzomib 15 mg/m2"},{"description":"Carfilzomib 20 mg/m2 on days -2, -1, +5, and +6 IV over 10 minutes.\n\nCohort 2: Carfilzomib 20 mg/m2: Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 20 mg/m2 on day -2, -1, + 5 and +6","id":"OG001","title":"Cohort 2: Carfilzomib 20 mg/m2"},{"description":"Carfilzomib 20 mg/m2 on days -2, -1 and +5 IV over 10 minutes.\n\nCohort 2b: Carfilzomib 20 mg/m2: Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 20 mg/m2 on day -2, -1 and + 5","id":"OG002","title":"Cohort 2b: Carfilzomib 20 mg/m2"},{"description":"Carfilzomib 27 mg/m2 on days -2, -1 and +5 IV over 10 minutes.\n\nCohort 3b: Carfilzomib 27 mg/m2: Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 27 mg/m2 on day -2, -1 and + 5","id":"OG003","title":"Cohort 3: Carfilzomib 27mgm2"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Assessed daily (while inpatient) through clinical and laboratory examinations up to 90 days.","title":"Neutrophil Engraftment","type":"SECONDARY","unitOfMeasure":"days"}